Mihran H. Shirinian
Experienced in Fibrosing Mediastinitis

Dr. Mihran H. Shirinian

Hematology
1505 Wilson Terr, Ste 340, 
Glendale, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Fibrosing Mediastinitis
1505 Wilson Terr, Ste 340, 
Glendale, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

To provide state of the art medical care for our patients in a friendly, and compassionate setting.

Dr. Shirinian is rated as an Experienced provider by MediFind in the treatment of Fibrosing Mediastinitis. His top areas of expertise are Acute Erythroid Leukemia (AEL), Colorectal Cancer, Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Cairo University
Specialties
Hematology
Licenses
Internal Medicine in CA
Board Certifications
Internal Medicine (Sub: Medical Oncology)
Internal Medicine
Hospital Affiliations
Keck Hospital Of USC
Glendale Adventist Medical Center
Languages Spoken
English
Arabic
Armenian
French
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Comprehensive Oncology Hematology Center
1505 Wilson Terr, Ste 340, Glendale, CA 91206

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Enrollment Status: Recruiting
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drug: Repotrectinib
Study Phase: Phase 1/Phase 2
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Enrollment Status: Active_not_recruiting
Publish Date: October 17, 2025
Intervention Type: Drug
Study Drugs: N-803, Pembrolizumab, Nivolumab, Atezolizumab, Avelumab, Durvalumab, PD-L1 t-haNK
Study Phase: Phase 2
Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drugs: N-803+Pembrolizumab, N-803+Carboplatin+Nab-paclitaxel+Pembrolizumab, N-803+Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed, Pembrolizumab, Carboplatin+Nab-paclitaxel or Paclitaxel+Pembrolizumab, Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed
Study Phase: Phase 3
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
View 3 Less Clinical Trials

1 Total Publications

Downstaging after preoperative chemoradiation for locally advanced rectal cancer is associated with better survival than pathologic stage 0-1 disease treated with upfront surgery.
Downstaging after preoperative chemoradiation for locally advanced rectal cancer is associated with better survival than pathologic stage 0-1 disease treated with upfront surgery.
Journal: International journal of colorectal disease
Published: December 24, 2023
Similar Doctors
Experienced in Fibrosing Mediastinitis
Dr. Michael Del Rosario
Hematology
Experienced in Fibrosing Mediastinitis
Dr. Michael Del Rosario
Hematology

Michael Del Rosario, MD Private Practice

2653 Elm Ave, Ste #300, 
Long Beach, CA 
 (24.0 miles away)
562-340-0606
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Del Rosario is a Hematologist in Long Beach, California. Dr. Del Rosario is rated as an Advanced provider by MediFind in the treatment of Fibrosing Mediastinitis. His top areas of expertise are Thrombocytopenia, Colorectal Cancer, Agranulocytosis, and Chronic Familial Neutropenia.

Experienced in Fibrosing Mediastinitis
Dr. Sarmen Sarkissian
Hematology
Experienced in Fibrosing Mediastinitis
Dr. Sarmen Sarkissian
Hematology

Pacific Shores Medical Group

1043 Elm Ave, Ste 104, 
Long Beach, CA 
 (25.7 miles away)
562-590-0345
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sarmen Sarkissian is a Hematologist in Long Beach, California. Dr. Sarkissian is rated as an Advanced provider by MediFind in the treatment of Fibrosing Mediastinitis. His top areas of expertise are WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Chromophobe Renal Cell Carcinoma, and Colorectal Cancer.

Experienced in Fibrosing Mediastinitis
Dr. Daniel J. Kim
Hematology Oncology | Oncology | Hematology
Experienced in Fibrosing Mediastinitis
Dr. Daniel J. Kim
Hematology Oncology | Oncology | Hematology

City Of Hope Medical Foundation

209 Fair Oaks Ave, 
South Pasadena, CA 
 (4.9 miles away)
626-396-2900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Kim is a Hematologist Oncology specialist and an Oncologist in South Pasadena, California. Dr. Kim is rated as a Distinguished provider by MediFind in the treatment of Fibrosing Mediastinitis. His top areas of expertise are Stomach Cancer, Chronic Familial Neutropenia, Agranulocytosis, and Blood Clots.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shirinian's expertise for a condition
ConditionClose
    View All 30 Distinguished Conditions
    View All 41 Advanced Conditions
    View All 130 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile